Meanwhile, the S&P BSE Sensex was up 108.74 points or 0.33% at 32,615.46.

Bulk deal boosted volume on the scrip. On BSE, so far 13.35 lakh shares were traded in the counter as against average daily volume of 40,149 shares in the past one quarter. The stock had hit a high of Rs 760 and a low of Rs 717.65 so far during the day. The stock had hit a record high of Rs 1,278.55 on 21 November 2017. The stock had hit a 52-week low of Rs 751.35 on 23 October 2017.

The stock had underperformed the market over the past one month till 23 October 2017, falling 4.55% compared with 1.83% rise in the Sensex. The scrip also underperformed the market in past one quarter, sliding 9.93% as against Sensex's 0.86% rise. The scrip also underperformed the market in past one year, declining 35.49% as against Sensex's 15.36% rise.

The mid-cap stock has equity capital of Rs 83.33 crore. Face value per share is Rs 10.

Dr. Lal PathLabs' consolidated net profit rose 11% to Rs 44.40 crore on 12.04% growth in total income to Rs 256.80 crore in Q1 June 2017 over Q1 June 2016.

Dr. Lal PathLabs is a provider of diagnostics and related healthcare tests and services in India. Customers include individual patients, companies and institutions, healthcare providers as well as hospital and clinical labs.